Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by PLITheOneon Aug 12, 2021 2:34pm
24 Views
Post# 33695115

Liminial would have had:

Liminial would have had:130M if they didn't do the deal with Kedrion
An approved drug to market - Ryplazm
A stste of the art technology, PPPS, to gain future revenue - Billions!

They essentially paid Kedrion $26M to take years of R&D at a cost close to $1 Billion!!

WTF! Are these guys idiots or is there another plan just like when they nderhandedly stole Prometic from long term investors!! Sounds like you know very little about this company and need to do a little research.

Pay attention! This will continue DOWN!!
<< Previous
Bullboard Posts
Next >>